PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy

PLGA based cancer immunotherapy incorporating antigen and TLR ligands has resulted in enhancement of the anti-tumour response. Here, the authors explore the use of a defined double stranded RNA adjuvant, Riboxxim, and test its incorporation with PLGA immunotherapy in the context of in vivo tumour mo...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Julia Koerner, Dennis Horvath, Valerie L. Herrmann, Anna MacKerracher, Bruno Gander, Hideo Yagita, Jacques Rohayem, Marcus Groettrup
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Q
Accès en ligne:https://doaj.org/article/49f713706d4f4e6c84d91492aa8a5fb5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!